Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study.

ABSTRACT:

Objective

Metformin produced weight loss and delayed or prevented diabetes in the Diabetes Prevention Program (DPP). We examined its long-term safety and tolerability along with weight loss, and change in waist circumference during the DPP and its long-term follow-up.

Research design and methods

The randomized double-blind clinical trial of metformin or placebo followed by a 7-8-year open-label extension and analysis of adverse events, tolerability, and the effect of adherence on change in weight and waist circumference.

Results

No significant safety issues were identified. Gastrointestinal symptoms were more common in metformin than placebo participants and declined over time. During the DPP, average hemoglobin and hematocrit levels were slightly lower in the metform

SUBMITTER: Diabetes Prevention Program Research Group 

PROVIDER: S-EPMC3308305 | biostudies-literature | 2012 Apr

REPOSITORIES: biostudies-literature